Market Wrap September 1, 2006
The markets were up broadly.
The DJIA was up .74% to 11,465.35.
The Nasdaq was up .43% to 2,193.22.
The S&P was up .55% to 1,311.03.
There was little movement among the big techs. Most traded within a narrow range, up or down less than 1% from yesterday. Broadcom was an exception. It dropped almost 5% to $27.96 after it IP case against Broadcom was thrown out of court.
Starbuck's rose almost 3% to $31.84, as its August same-store sales beat Wall St estimates.
Over on the NYSE, Bristol-Myers rose 5.5% after a federal court said that a generic version of the drug Plavix could not be sold in the US until a trial on the matter is settled. Plavix is BMY's largest money-maker.
Shares in Intergraph were up 17% to $43.88 on news that a private equity group would buy the company.
Revlon's shares moved up almost 9% to $1.41. On Wednesday, the WSJ ran an article saying that insiders were buying the stock.
Douglas A. McIntyre
The DJIA was up .74% to 11,465.35.
The Nasdaq was up .43% to 2,193.22.
The S&P was up .55% to 1,311.03.
There was little movement among the big techs. Most traded within a narrow range, up or down less than 1% from yesterday. Broadcom was an exception. It dropped almost 5% to $27.96 after it IP case against Broadcom was thrown out of court.
Starbuck's rose almost 3% to $31.84, as its August same-store sales beat Wall St estimates.
Over on the NYSE, Bristol-Myers rose 5.5% after a federal court said that a generic version of the drug Plavix could not be sold in the US until a trial on the matter is settled. Plavix is BMY's largest money-maker.
Shares in Intergraph were up 17% to $43.88 on news that a private equity group would buy the company.
Revlon's shares moved up almost 9% to $1.41. On Wednesday, the WSJ ran an article saying that insiders were buying the stock.
Douglas A. McIntyre
<< Home